Anlicon: The company currently has only one innovative drug project under research, which is still in the Phase I clinical trial stage.

On April 19, Oncall announced that the closing price of the company's stock had deviated by more than 20% for three consecutive trading days, which is considered abnormal stock trading volatility according to the relevant provisions of the Shenzhen Stock Exchange Trading Rules. Currently, the company only has one innovative drug project in research, which is the ALK-N001 project and is still in phase I clinical trials as of the date of this announcement. On August 26, 2025, the company signed a Strategic Cooperation Agreement and Authorization Agreement with Yafei Biomedical Technology Co., Ltd. and Shanghai ProLia Biomedical Technology Co., Ltd. regarding the ALK-N002 project. As of the date of this announcement, this matter has been approved by the company's shareholders' meeting, and Yafei Biomedical and ProLia are still going through internal approval procedures. The company reminds investors to make rational investment decisions and be aware of investment risks.